26 results about "Circulating tumor cell" patented technology

This invention relates to a method and application for enriching circulating tumor cells (CTCs) based on ambient temperature mechanical perfusion technology, belonging to the field of biomedical technology. The method comprises the following steps: flushing the liver resected during liver transplantation via the portal vein and hepatic artery, connecting it to an ambient temperature mechanical perfusion loop, and performing in vitro perfusion using simulated blood perfusion fluid; when perfusion exceeds 2 hours and the lactate content drops to <5 mmol / L, collecting the simulated blood perfusion fluid; and sequentially subjecting the simulated blood perfusion fluid to centrifugation, red blood cell removal, and white blood cell removal to obtain enriched circulating tumor cells (CTCs) for liver cancer. A human liver cancer ex vivo organ perfusion model is constructed using NMP technology to fully recreate the tumor microenvironment and CTC generation process, and the large volume of perfusion fluid is processed to achieve efficient enrichment of CTCs.

The utility model discloses a kind of circulating tumor cell in vitro culture fluid filtering devices, including shell, the bottom surface of the shell is fixedly installed with rotating motor, the inner bottom wall of the shell is inlayed with first bearing, the inner ring of the first bearing is fixedly connected with rotating rod, the output end of the rotating motor is connected with the bottom end of rotating rod by first bearing, the upper surface of the rotating rod is fixedly connected with clamping block. The cooperation of the device through clamping groove and clamping block, realize rotating motor and filter frame flexible separation, by inserting the insert block of cover plate bottom into storage groove, and using positioning assembly to position cover plate, make synchronous assembly extrude filter frame, the phenomenon of displacement occurs when filter frame rotates, realize that filter frame is conveniently disassembled and installed, to facilitate subsequent maintenance and cleaning, to solve the disassembly of the filter screen of existing device is more cumbersome, leading to the problem of lower work efficiency.

This invention belongs to the field of cell sample detection and provides a microfluidic chip for separating circulating tumor cells (CTCs) based on size and aptamers. The invention includes a functional layer with a sample outlet and a sample inlet, and a cell substrate disposed on the upper and lower surfaces of the functional layer. The sample outlet and sample inlet of the functional layer are connected by a separation channel, which includes at least one micropillar array capable of carrying an EpCAM aptamer. The micropillar array is composed of a capture channel surrounding at least two micropillar structures. One end of the micropillar array is connected to the sample inlet, and the other end of the micropillar array has a gradient retention channel connected to the sample outlet. The microfluidic chip uses EpCAM aptamers to modify the micropillar array, increasing the number of collisions between CTCs and the chip, and increasing the probability of collisions between circulating tumor cells and the aptamers on the micropillar surface. Secondly, by utilizing the high specificity of the aptamer for tumor cells, the accuracy and specificity of separation are improved.

Provided is a device for screening and separating circulating tumor cells (CTCs), comprising: a chamber module, the chamber module being provided with a mixing chamber, a screening chamber and a waste liquid chamber, and the mixing chamber, the screening chamber and the waste liquid chamber being sequentially communicated; a control module, the control module being mounted on the chamber module, and the control module being configured to control, according to the motion state thereof, whether to discharge a liquid from the mixing chamber to the screening chamber; a temperature control module, the temperature control module being mounted on the chamber module, and the temperature control module being configured to control the temperature in the mixing chamber; and a magnetic enrichment module, the magnetic enrichment module being configured to form a magnetic field in the mixing chamber. Provided is the device for screening and separating CTCs on the basis of immunomagnetic bead separation technology. The device has a compact structure and a small size, is convenient to operate, and has the function of simulating the constant-temperature environment in human bodies to assist in reaction incubation, thereby ensuring the reliability and precision of detection.

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.

This invention belongs to the field of biomedical technology and provides a high-throughput drug screening system and its usage method for enriching circulating tumor cells (CTCs) in liver cancer. It includes an information processing and control unit; a diseased liver perfusion device comprising an organ chamber containing injection fluid at the bottom, an arterial supply line, an arterial end sensor, an arterial end clamp valve, at least two membrane lungs, a portal vein supply line, a portal vein end clamp valve, and a portal vein end sensor; a CTC enrichment device, which uses erythrocyte lysis to remove erythrocytes and immunomagnetic bead labeling to remove leukocytes, enabling the processing of large volumes of perfusion fluid in a single step to obtain enriched circulating tumor cells; a high-throughput drug screen; and phototubes, arterial end sensors, and portal vein end sensors, each electrically connected to the information processing and control unit. Compared with existing technologies, the high-throughput drug screening system and its usage method of this invention have the advantages of establishing a room-temperature mechanically perfused ex vivo liver cancer model, realizing the processing of large volumes of liquid specimens, and providing automated high-throughput drug screening functionality.

The application discloses a tumor cell risk assessment method, device, equipment and storage medium. The method comprises the following steps: acquiring a target marker detection image corresponding to a circulating tumor cell of a target patient; determining a first marker color difference and a second marker color difference corresponding to the target marker detection image based on the target marker detection image; inputting the first marker color difference and the second marker color difference into a tumor cell concentration detection model for cell concentration detection; and determining a target risk assessment result corresponding to the target marker detection image based on an output result of the tumor cell concentration detection model. The application can realize automatic risk assessment of circulating tumor cells, greatly reduce labor costs, improve tumor cell risk assessment efficiency, and thus ensure the stability and repeatability of the risk assessment result.

This invention relates to the field of biodetection technology, providing a logic-gated nanogel probe for live cell typing and its preparation method. The invention uses a thermosensitive polymer nanogel as a carrier, with its surface covalently modified with an antibody that specifically binds to the EGFR L858R mutant protein and a peptide nucleic acid that specifically binds to miR-21. Internally, it encapsulates a self-quenched fluorescent dye. The probe employs an AND logic gating design, triggering gel network dissociation and dye release to generate a fluorescent signal only when it simultaneously recognizes the EGFR L858R protein on the cell surface and captures miR-21 within the cell. This invention solves the problems of high false positive rates in existing single-target detection methods and the inability of traditional liquid biopsy techniques to perform simultaneous genotype-phenotype analysis in situ on live cells. It achieves highly specific and sensitive in situ interpretation of circulating tumor cells, and has significant application value in the field of precision diagnosis and treatment of lung cancer.

The present invention relates to a method (500) for microfluidic preparation of a sequencing library of nucleic acid-containing cells (40), in particular circulating tumor cells (40), wherein particles (50) are added to a liquid (10) comprising nucleic acid-containing cells (40), in particular circulating tumor cells (40), wherein the particles (50) each comprise at least one cell-binding entity (51), in particular at least one anti-EpCAM antibody, and one or more sequencing entities (52), preferably oligonucleotides, in particular primers, and / or enzymes, in particular polymerases, wherein after the addition (504), preferably at least some of the cells (40) that have each bound one or more of the particles (50) via the cell-binding entity (51) are separated (505) in order to subsequently construct a sequencing library.

The utility model discloses a kind of circulating tumor cell physical and chemical screens, including body, reaction tank is equipped in the body, liquid inlet area, first reaction zone, second reaction zone and drainage area are provided in the reaction tank, first flow channel is arranged in the first reaction zone, the second flow channel in the second reaction zone is distributed in spiral shape, the end of the second flow channel is connected with drainage area.The utility model, first reaction zone combines white blood cell, carries out negative selection, CTC cell is enriched in the second reaction zone, carries out positive selection, can better reduce the interference of white blood cell to experiment, improve the detection rate of CTC cell;And;Second flow channel is arranged in the second reaction zone in spiral shape distribution, it is favorable to the CTC captured evenly distributed in different positions of spiral flow channel, reduce the interference caused by cell stacking to microscopy.

The application discloses a method for detecting circulating tumor cells based on cell membrane surface sialic acid expression quantity and single cell detection technology, and belongs to the field of biomedical technology. The method comprises the following steps: using a boron acid group modified probe to label cell surface sialic acid in a blood sample after erythrocyte lysis; passing the labeled sample through a phase transfer flow focusing chip to enrich and purify circulating tumor cells based on cell size; and detecting the enriched and purified cells by a single cell analysis method. The application solves the problems of high cost, long time consumption and high missed detection rate of the current circulating tumor cell detection method applied in clinical practice, and provides a method with simple operation and higher universality for circulating tumor cell detection.

The present invention realizes: a method for freezing a sample containing peripheral circulating tumor cells, with which the number of false positives is reduced and good reproducibility is obtained; and use of the same. The present invention uses a method for freezing a sample containing peripheral circulating tumor cells, the method comprising a step for freezing a sample containing peripheral circulating tumor cells in a cryoprotective solution containing a complex lipid (excluding a cryoprotective solution containing a plasma component).

A marker group for detecting osteosarcoma circulating tumor cells (CTCs), characterized in that the marker group is COL1A2 isoforms, and the COL1A2 isoforms include at least one of ENST00000620463 and ENST00000297268. Compared with the prior art, the COL1A2 isoforms provided by the present application have a high prevalence in osteosarcoma tissues, a combined detection rate of 98.56%, and a detection rate of 85.71% in metastatic patients; the area under the ROC curve (AUC) of CTCs detection for predicting osteosarcoma metastasis is 0.833, which is better than traditional markers; longitudinal follow-up can detect metastasis 5.11 months earlier than imaging; it can distinguish metastatic patients before operation, and has unique applicability to osteosarcoma with low mutation burden. In addition, the COL1A2 isoforms can complement tumor-aware detection, and can be used for prognosis and monitoring of metastasis and recurrence of osteosarcoma patients who cannot successfully customize circulating tumor DNA detection panel (ctDNA panel).

The invention discloses an enhanced homologous targeting detection probe as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The enhanced homologous targeting detection probe is a metal complex, raw materials comprise amino acid, cobalt ions and lanthanide ions, the amino acid is histidine, and the cobalt ions Co and the lanthanide ions are sequentially reacted with the histidine through coordination. The metal complex can be used for preparing a product for detecting circulating tumor cells or tumor extracellular vesicles in plasma in vitro. The invention provides an efficient, accurate and economical circulating tumor marker detection means, and based on the same'super homologous targeting 'core principle, high-sensitivity detection of CTC and tumor EV is realized.

1. The name of the design product: circulating tumor cell screening separator. 2. The use of the design product: circulating tumor cell screening separator for circulating tumor cell screening separation. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

This invention discloses a biomimetic nanobamboo based on centrally rigid tandem assembly (CRSA) technology and its application in the isolation of circulating tumor cells (CTCs). This biomimetic nanobamboo uses rigid triangular structural units with a Y-shaped framework as lateral partitions, and is longitudinally tandemly linked by rolling circle amplification products (sRCAp), cross-linked with linker molecules to form a super-large, highly rigid nanobamboo structure. Surface modification with targeted aptamers acts as "branches," and biotin modification is used for magnetic separation. This invention achieves highly efficient assembly of the nanobamboo using CRSA technology, with an assembly efficiency of 90%. Its structural rigidity is 33 times higher than that of traditional DNA nanotubes, and its resistance to nuclease degradation is enhanced by 30 times. Utilizing the multivalent aptamer binding effect and magnetic separation technology, this biomimetic nanobamboo can efficiently separate rare CTCs from whole blood samples, achieving a separation efficiency of 68.2 times and a purity of 75.6%, while maintaining good activity of the separated CTCs. This invention provides a novel tool for the precise isolation of CTCs and has significant application prospects in tumor metastasis early warning and precision medicine.

This invention belongs to the fields of biotechnology and precision oncology, and discloses a serum-free amplification method for circulating tumor cells (CTCs) based on apoptosis selectivity, along with a dedicated culture medium. This addresses the problems of existing CTC technologies, which rely on physical capture leading to impaired cell viability and low culture success rates. The invention involves mild density gradient centrifugation and erythrocyte lysis of anticoagulated whole blood from patients to obtain a mixed population of leukocytes containing CTCs. This population is then seeded into a serum-free, selective apoptosis medium for three-dimensional culture. The medium contains apoptosis inhibitors and specific growth factors. Utilizing the difference between tumor cells' anti-apoptosis and normal blood cells' susceptibility to apoptosis, leukocyte apoptosis is induced within 4-7 days, while simultaneously supporting CTC survival, adhesion, and clonal proliferation, enabling the amplification of individual CTCs into cell clusters. This method preserves the original activity and heterogeneity of CTCs, is simple to operate, and has good reproducibility, providing a highly active cell source for CTC molecular identification, drug sensitivity testing, and metastasis mechanism research.

This invention relates to γδT cell culture technology, specifically a method and application for activating γδT cells using circulating tumor cells (CTCs) or their derivatives. The method includes obtaining donor-derived γδT cells; obtaining CTCs or their derivatives from cancer patients; and co-culturing the γδT cells with the CTCs or their derivatives in an in vitro co-culture system, thereby activating the γδT cells under the stimulation of the CTCs or their derivatives to obtain CTC-γδT cells. This invention utilizes patient-derived circulating tumor cells as the activation stimulus for γδT cells, enabling the resulting γδT cells to recognize tumor-associated antigens and personalized neoantigens, overcoming tumor heterogeneity and antigen escape problems.

This invention relates to the field of pharmaceutical technology, specifically to an engineered long-acting platelet delivery system for loading therapeutic drugs, its preparation method, and its applications. The system comprises platelets loaded with therapeutic drugs and nanoparticles containing platelet apoptosis inhibitors. The engineered long-acting platelet delivery system of this invention enables stable in vitro storage and long-term in vivo circulation. Furthermore, by leveraging the efficient and natural wound tropism and tumor targeting properties of platelets, this system can precisely target residual and circulating tumor cells after surgery, thereby releasing cytotoxic chemotherapeutic drugs and effectively preventing postoperative tumor recurrence and metastasis.

This invention belongs to the field of biomedical technology, specifically relating to a method and kit for improving the sensitivity and specificity of circulating tumor cell (CTC) detection. The method first treats anticoagulated blood with erythrocyte lysis buffer, centrifuges to obtain a cell suspension (including leukocytes and circulating tumor cells); then, a radiosensitizer is added and the suspension is irradiated; next, single-cell gel electrophoresis is used to detect the degree of DNA damage in the test cells; finally, leukocytes and tumor cells are distinguished based on cell morphology using a fluorescence microscope or fluorescence scanner. This invention is the first to detect the number and type of circulating tumor cells (CTCs) in peripheral blood based on ionizing radiation and radiosensitization effects, according to the degree of DNA damage in tumor cells. Compared with existing technologies, this detection method and kit are not only simple and rapid, but also significantly improve detection sensitivity and specificity. Furthermore, it is independent of the physical properties of cells and tumor cell surface markers, requires a small sample volume, is highly versatile, and can detect CTCs in different types of solid tumors.

This utility model discloses an integrated microfluidic circulating tumor cell sorting device, relating to the field of cell sorting technology. It includes a scaffold, a sample injection device, and a microfluidic chip; it also includes a closed storage box fixed to the scaffold; the microfluidic chip is disposed inside the closed storage box, and the sample injection device is partially and sealed inside the closed storage box; a gas evacuation device is used to create a negative pressure vacuum inside the closed storage box; a return gas valve and a pressure sensor are respectively fixed to the closed storage box and communicate with its interior. The advantages of this utility model are: by placing the microfluidic chip inside the closed storage box, and using the gas evacuation device to create a negative pressure vacuum inside the closed storage box, and then drawing in a suitable pressure under the detection of the pressure sensor, the pressure difference between the inside and outside of the bubble decreases sharply under a certain negative pressure, causing expansion. At this point, the bubble wall thickness thins to the critical rupture thickness and spontaneously ruptures. Furthermore, the negative pressure environment only changes the gas phase pressure, avoiding microjets lost due to ultrasonic cavitation, resulting in low impact on cells and good protection.